Expression of Matrix Metalloproteinase 9 Is a Prognostic Factor in Patients with Non-Hodgkin Lymphoma

Cancer

Volumn 100, Issue 2, 2004, Pages 356-365

  Sakata, Koh Ichi ^a   Satoh, Masaaki ^a   Someya, Masanori ^a   Asanuma, Hiroko ^a   Nagakura, Hisayasu ^a   Oouchi, Atushi ^a   Nakata, Kensei ^a   Kogawa, Katsuhisa ^a   Koito, Kazumitsu ^a   Hareyama, Masato ^a   Himi, Tetsuo ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Epstein Barr encoded small RNA 1 (EBER1); Matrix metalloproteinase 2 (MMP2); Matrix metalloproteinase 9 (MMP9); Non Hodgkin lymphoma (NHL); Prognostic factor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GELATINASE A; GELATINASE B; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; T CELL LYMPHOMA;

ADULT; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; RNA, VIRAL; SURVIVAL RATE;

EID: 9144242962     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11905     Document Type: Article

References (35)

1. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-2135.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
3. Harris NL, Jaffe ES, Diebold I, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
5. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 1991;51(18 Suppl):5054s-5059s.
6. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197-250.
7. Liotta LA. Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986;46:1-7.
8. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer. 1996;73:1401-1408.
9. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996;7:147-154.
10. Sakata K, Matsumoto Y, Tauchi H, et al. Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int J Radiat Oncol Biol Phys. 2001;49:161-167.
11. Montone KT, Brigati DI. In situ molecular pathology: instrumentation, oligonucleotides, and viral nucleic acid detection. J Histotechnol. 1994;17:195-201.
12. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
13. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer. 1997;80:2311-2320.
14. Kadin ME, Berard CW, Nanba K, Wakasa H. Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States-Japan Seminar, September 6 and 7, 1982, in Seattle, Washington. Hum Pathol. 1983;14:745-772.
15. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem. 1986;55:1037-1057.
16. Moscatelli D, Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta. 1988;948:67-85.
17. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336.
18. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 1996;56:5279-5284.
19. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol. 1998;152:591-596.
20. Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 1998;58:2209-2216.
21. Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, Edwards DR. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res. 1993;5:19-28.
22. Kossakowska AE, Hinek A, Edwards DR, et al. Proteolytic activity of human non-Hodgkin's lymphomas. Am J Pathol. 1998;152:565-576.
23. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
24. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20:103-111.
25. Takeshita H, Yoshizaki T, Miller WE, et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol. 1999;73:5548-5555.
26. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1993;90:9150-9154.
27. Yoshizaki T, Sato H, Furukawa M, Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci U S A. 1998;95:3621-3626.
28. Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer. 2000;89:715-723.
29. Hamilton-Dutoit SJ, Pallesen G. Detection of Epstein-Barr virus small RNAs in routine paraffin sections using non-isotopic RNA/RNA in situ hybridization. Histopathology. 1994;25:101-111.
30. Zhou XG, Hamilton-Dutoit SJ, Yan QH, Pallesen G, High frequency of Epstein-Barr virus in Chinese peripheral T-cell lymphoma. Histopathology. 1994;24:115-122.
31. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54:182-190.
32. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351-2356.
33. Liang R, Chen F, Lee CK, et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant. 1997;19:91-93.
34. Nawa Y, Takenaka K, Shinagawa K, et al. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:1321-1322.
35. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178-193.